Exclusive worldwide distribution agreement with ITSI Bioscience LLC.

GenTegra LLC a leading company in the technology for ambient stabilization of nucleic acids, proteins, phage and other biomolecules , today announced it has signed an exclusive worldwide distribution agreement with ITSI Bioscience LLC. Under the terms of the agreement, ITSI Biosciences will be the exclusive worldwide distributor for the GenTegra’s GenPlate® line of high […]

GenProtect RNA version II Early Access Program begins

GenProtect tRNA II is a new implementation of the original GenProtect card with significant performance enhancements over the original GenProtect card. GenProtect tRNA II is the only collection card available that is specifically designed with collection of RNA as its express function. GenProtect tRNA II is a combination of laboratory grade Ahlstrom-Munksjö paper treated with Active Chemical Protection™ for RNA samples. There has been a long-standing need for a way to collect RNA samples in remote areas where providing a cold chain to protect the RNA as it is sent to the analysis lab is extremely difficult, very expensive or both. The version II beta release of GenProtect tRNA II can protect RNA at ambient temperatures to +70C for many weeks while it is shipped back to the analysis laboratory. The Active Chemical Protection added to the paper is an enhanced chemistry version of GenTegra-RNA applied to the paper matrix. Beta samples are now available through the GenTegra early access program. GenProtect RNA II extends the RNA stability to more than a month. Quantities of the GenProtect tRNA II card may be obtained by contacting GenTegra LLC.

Contact: James Nelson, VP Marketing

jamesn@gentegra.com

GenTegra LLC $2.8M SBIR Grant for RNA Collection cards

PLEASANTON, CA – GenTegra, LLC was awarded a prestigious Phase IIb Small Business Innovation Research (SBIR) grant for $2.8 million from the National Institute of Allergy and Infectious Disease (NIAID).

This three-year grant will fund the development of filter paper technologies for the collection and stabilization of RNA virus and total RNA in whole blood, plasma at ambient temperatures and for subsequent shipping to and analysis at a centrally located laboratory. “This effort will expand the company’s ability to provide advanced technologies by extending the power of its ambient temperature preservation technologies to the field collection of labile microbial pathogens: Zika and other Flaviviruses in particular, while preserving the total complement of RNA in whole blood at ambient,” President Shanavaz Nasarabadi said in a statement.

“Our new, paper-based technology will provide formulations that are fully REACH-ECHA compliant and thus suitable to international-scale blood sample field collection, shipping, and storage in the complete absence of refrigeration at any step,” GenTegra CSO Dr. Michael Hogan added.

Pleasanton, California-based GenTegra LLC is a world leader in developing Active Chemical Protection™ technologies for the ambient dry storage of DNA, RNA, proteins, and other biological molecules and reducing the costs of maintaining biobanks and biorepositories for individual researches, pharmacogenomics companies, and hospitals.

GenTegra, LLC has been developing paper-based nucleic acid stabilizing products with its commercialization partner Ahlstrom-Munksjö since 2013 and launched its first commercial product, Ahlstrom-Munksjö GenSaver™ DNA Collection Card, in 2016. The Ahlstrom-Munksjö GenSaver™ card was the result of primary research accomplished under DARPA funded R&D grants and was commercialized using GenTegra’s core technologies for preserving nucleic acids, GenTegra®-DNA and GenTegra®-RNA.

Read more

GenTegra Launches new Ahlstrom GenSaver™ 2.0 Forensic card

However, forensic customers were asking for a GenSaver card that provided a more positive and stronger antimicrobial property to better ensure the long-term satiability of the DBS samples. This desire and request is the basis of the GenSaver 2.0 card which is the GenSaver 1.0 card with the addition of a specific antimicrobial to the GenTegra-DNA chemistry on the GenSaver card. Long term testing has been underway for some time now to provide accelerated data to confirm high quality protection of the DNA for >20 years with the addition of this strong antimicrobial added. Data at every stage is showing the same high level of DNA protection with the added protection of a strong antimicrobial for additional long term protect while in storage. The cards still require storage in a controlled humidity but not the added antimicrobial acts as insurance against microbial contamination.

GenSaver 2.0 DNA cards are specifically enhanced to fit the needs of the forensic market. By adding an antimicrobial to the DNA protection formula of the GenSaver 1.0 card. The added antimicrobial provides additional protection for the often-contaminated samples obtained in a forensic collection. The addition of the antimicrobial makes the GenSaver 2.0 the best choice when concerned about possible microbial contamination of a DNA sample.

The GenSaver 2.0 card maintains it superior protection and ability to provide substantially high yields of DNA then the classic FTA card. GenSaver 2.0 should be the card of choice for all forensic sample collections.

Read more

GenProtect RNA beta launch

GenProtect RNA is the only collection card design specifically with collection of RNA as its express function. GenProtect is a combination of laboratory grade Ahlstrom paper treated with GenTegra-RNA to provide protection. There has been a long-standing need for a way to collect RNA samples in remote areas where providing a cold chain to protect the RNA as it is sent to the analysis lab is extremely difficult, very expensive or both. The version 1 beta release of GenProtect can protect RNA at ambient temperatures (-80C to +70C) for a week while it is shipped back to the lab. The active chemical protection added to the paper is the same chemistry available in GenTegra-RNA only it has been applied to the paper matrix. Beta samples have been made available as work is underway on version 2 GenProtect which will extend the RN stability to a month of more. Small quantities of the GenProtect card may be obtained by contacting GenTegra.

Contact: James Nelson, VP Marketing

jamesn@gentegra.com

1-925-461-3010

GenTegra LLC $1.8M SBIR Grant for RNA

PLEASANTON, CA – The National Institutes of Health has awarded an approximately $1.8 million Phase IIB Small Business Innovation Research (SBIR) grant by National Institute of Allergy and Infectious Disease (NIAID) to ambient chemical protection company GenTegra LLC.

The two-year grant will fund the development of filter paper technology for the collection and stabilization of RNA virus in whole blood and plasma at ambient temperatures and for subsequent shipping to and analysis at a centrally located laboratory. “This effort will expand the company’s ability to provide advanced technologies by extending the power of its ambient temperature preservation technology to the field collection of labile microbial pathogens: Zika and other Flavi viruses in particular,” CEO R. Bruce Jamieson said in a statement.

“Our new, paper based technology will also provide formulations that are fully REACH-ECHA compliant,” GenTegra CSO Dr. Michael Hogan added.

Pleasanton, California-based GenTegra LLC is a world leader in developing Active Chemical Protection™ technologies for the ambient dry storage of nucleic acids and other biological molecules and reducing the costs of maintaining biobanks and biorepositories for individual researches, pharmacogenomics companies, and hospitals.

GenTegra LLC has been developing paper-based nucleic acid stabilizing products with its commercialization partner Ahlstrom-Munksjö since 2013 and launched its first commercial product, Ahlstrom-Munksjö GenSaver™ DNA Collection Card, in 2016. The Ahlstrom-Munksjö GenSaver™ card was the result of primary research accomplished under DARPA funded R&D grants and was commercialized using GenTegra’s core technologies for preserving nucleic acids, GenTegra®-DNA and GenTegra®-RNA.

Contact: James Nelson, VP Marketing

jamesn@gentegra.com

1-925-461-3010

Ahlstrom GenSaver™ collection card for Dried Blood Spots (DBS)

GenTegra LLC and Ahlstrom have launched a new DBS collection card that provides superior protection for the DNA in DBS. Available in all the common and expected formats, they provide protection of the DNA in DBS for >20 years without freezing. The combination of a superior paper and GenTegra®-DNA, Active Chemical Protection™ allows direct addition of a small punch of the DBS to all downstream molecular biology applications, eliminating the need to wash inhibitory chemicals from the DBS. The better protected DNA is ideal for long read sequencing techniques.

Contact: James Nelson, VP Marketing

jamesn@gentegra.com

1-925-461-3010

Texas A&M AgriLife Research and GenTegra LLC are awarded contract continuation

Ambient Temperature Biospecimen Collection, Transport & Banking For Simplified Animal Disease Screening

Pleasanton, Calif.—The National Center for Foreign Animal and Zoonotic Disease Defense (FAZD Center) and GenTegra LLC today announced the awarding of a joint collaboration to continue work on the “Matrix Chaperone” sample collection device. The FAZD Center is a U.S. Department of Homeland Security (DHS) Science and Technology Center of Excellence and is led by Texas A&M AgriLife Research, an agency of The Texas A&M University System.

Texas A&M University System Chancellor, John Sharp, endorsed this effort, “Our ultimate goal here is to advance research toward new and better solutions, improving people’s lives. This collaboration with GenTegra is a great example of how higher education and industry can develop life-changing technology.”

The overall goal of this project is to develop and validate a new technology to enhance the collection, preservation, and shipping of disease outbreak samples to the diagnostic laboratory. The project applies a novel dry-state ambient temperature technology (Matrix Chaperone), developed at GenTegra towards enhancing sample preservation to allow for more robust downstream testing. The initial proof-of-concept study focused on utilizing the technology with avian samples in both a laboratory and field setting. Funded by the DHS Science and Technology Directorate’s Chemical and Biological Defense Division, the expansion of this proof-of-concept study will involve evaluation of this technology under field conditions, with both swabs and serum from avian sources.

The Matrix Chaperone technology would eliminate the need for cold-chain storage (refrigerated or frozen), both simplifying the process and enhancing sample preservation during the movement of samples from the field to the laboratory. This technology has broad applications both in the U.S. and globally.

GenTegra has completed pilot scale manufacturing of a series of customized swabs, and bench testing and field sampling are underway. In response to feedback from researchers at the FAZD Center, GenTegra developed multiple sizes of the swab to enable sampling of birds and livestock, and have begun sampling in the field.

The FAZD Center performs research and develops products to defend the nation from high-consequence foreign animal, emerging and zoonotic diseases. Founded in April 2004 as a DHS Science and Technology Center of Excellence, the FAZD Center works with investigators, end users and stakeholders to develop products that meet identified national priorities and help protect the agricultural critical infrastructure and the economy. The Center has robust programs in disease discovery, information technology, knowledge products, education and training curriculum, policy development, and technology commercialization.

GenTegra-RNA dry Bulk is in stock and ready for immediate shipment.

Contact:
Melissa Berquist, Ph.D
Associate Director
mlberquist@ag.tamu.edu
phone: 979.845.2855

GenTegra LLC has redefined ambient temperature stabilization of nucleic acids and other biomolecules through proprietary chemistries that protect and preserve in a biological matrix or as purified. In liquid form, the products protect specimens while being processed and when dried specimens are protected for years.

Contact: James Nelson, VP Marketing

jamesn@gentegra.com

1-925-461-3010

Tasso and GenTegra simplify blood draws, awarded $3M expansion

Madison, Wis., and Pleasanton Ca., April 7, 2015 — Tasso, Inc., a medtech start-up developing the HemoLink™, a small disposable device to simplify blood sampling, has secured an additional $2.9M in grant funding to advance its HemoLink technology with its development partner GenTegra LLC.

Based on progress made in developing the HemoLink, the Defense Advanced Research Projects Agency (DARPA) has expanded Tasso’s ongoing Phase II SBIR contract. Tasso and GenTegra are developing an integrated device that is able to collect blood from patients and stabilize biomarkers at ambient temperatures without requiring cold chain transportation. The stabilization component of the grant is a $1.3M allocation to GenTegra LLC, whose Matrix Chaperone™ technology is redefining the boundaries of ambient sample stabilization.

Dr. Erwin Berthier, VP of Tasso and principal investigator on the contract, emphasized, “This is a disruptive technology that will enable connecting anyone in the world – from home, rural areas, low resource locations, or war zones – to a centralized blood analysis laboratory, providing affordable cutting edge diagnostics to everyone.”

The HemoLink device safely collects blood from the surface of the skin, effectively replacing the need for venipuncture across a broad number of diagnostic tests.  The Matrix Chaperone stabilizes biospecimens at a broad range of ambient temperatures in order to preserve the vast diagnostic data offered by a blood sample. This combination of disruptive technologies fundamentally changes the way blood testing is done, replacing hospital-centric testing with testing focused on the user. Tasso President, Ben Moga states, “Together, this powerful HemoLink-Matrix Chaperone combination will modernize the diagnostic process by providing superior and affordable ‘in home’ and ‘point of care’ access to healthcare.”

Bruce Jamieson, CEO of GenTegra, offers, “GenTegra is pleased to be working with the innovative HemoLink device that Tasso is developing as an alternative to venipuncture blood collection. As a part of the HemoLink device our stabilization chemistry, Matrix Chaperone, stabilizes the blood in dry form for convenient shipping and any queue time at the clinical lab while waiting for diagnostic testing. The temperature range that is protected coincides with commercial carriers’ specifications, enabling the shipment of specimens in a simple mailer – free from cold chain requirements. The combination of a simple blood collection device and stabilization of the specimen at ambient temperatures will open many possibilities for new innovative ‘in home’ and ‘point-of-care’ sample collection scenarios.”

GenTegra LLC has redefined ambient temperature stabilization of nucleic acids and other biomolecules through proprietary chemistries that protect and preserve in a biological matrix or as purified. In liquid form, the products protect specimens while being processed and when dried specimens are protected for years.

Contact: James Nelson, VP Marketing

jamesn@gentegra.com

1-925-461-3010

Protect your RNA samples immediately, and for all its tomorrows

GenTegra LLC launches new RNA ambient stabilization product

GenTegra LLC, Pleasanton, CA, announces launch of GenTegra®-RNA dry Bulk.

GenTegra-RNA is groundbreaking technology for the stabilization, transport and storage of purified RNA. GenTegra is a water-soluble, inert chemical matrix that inactivates trace RNase in the liquid phase, providing an added level of RNA stability during sample handling, with or without using an ice bucket. In the dry-state, GenTegra-RNA imparts thermal stability at temperatures ranging from -80°C to 76°C and ensures quantitative recovery of RNA upon rehydration.

With the addition of GenTegra-RNA dry BULK to its line of products GenTegra LLC now offers a product that is ideally suited for automated processing of RNA samples. Mike Hogan, GenTegra’s CSO stated, “I am proud that dry bulk form of GenTegra-RNA allows us to offer its protection to applications that were not previously feasible. Researchers now have GenTegra-RNA in a form that is ideal for stabilizing RNA samples during automated processing.” As delivered the product has an unlimited shelf life and is ready for use by simply adding water.

Using GenTegra-RNA early in the RNA purification process provides protection at the earliest possible moment to ensure the highest possible yield of RNA. The protection extends to virtually all forms of RNA. After sample processing the RNA solution can be dried for permanent safe ambient storage of the sample until needed.

GenTegra-RNA is ideal for protecting RNA samples that need shipping from one research lab to another. Protection from GenTegra-RNA spans the complete range of temperatures defined by both FedEx shipping and for military uses. Full protection is provided in the range of -80°C to +56°C for up to 7 months. When stored at ambient temperatures the samples are completely stable for years.

GenTegra-RNA also protects through multiple rehydration and re-drying cycles allowing up to five aliquots to be taken from the sample over time.

GenTegra-RNA dry Bulk is in stock and ready for immediate shipment.

Contact: James Nelson, VP Marketing

jamesn@gentegra.com

1-925-461-3010